|
DOSAGE
|
Conjunctivitis: 1-2 gtts q2-4hr x 2days, QID x 5 days
|
|
Corneal Ucler: Days 1-2: Instill 1 to 2 gtts q30mins while awake. Awaken at approximately 4 and 6 hours after retiring and instill 1 to 2 drops. Days 3-7: 1 to 2 gtts q1hr while awake. Days 7-9 through treatment completion: 1gtt QID
|
|
INDICATIONS
|
OCUFLOX® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria
|
|
MECHANISM OF ACTION
|
fluoroquinolone (2nd) Binds bacterial DNA gyrase
|
|
MICROBIOLOGY
|
Broad spectrum, effective against Pseudomonas aeruginosa poor choice for chlamydia and mycoplasma.
|
|
Ofloxacin has been shown to be active against most strains of the following organisms both in vitro and clinically, in conjunctival and/or corneal ulcer infections AEROBES, GRAM-POSITIVE Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae AEROBES, GRAM-NEGATIVE Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens* ANAEROBIC SPECIES: Propionibacterium acnes
|
|
CONTRAINDICATIONS & WARNINGS
|
OCUFLOX® solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication Excellent corneal penetration. Second-generation fluoroquinolone antibiotics were good topical agents due to wide spectrum of antimicrobial activity, low toxicity, high potency, prolonged tear film concentration, and stability in solution.
|
|
PREGNANCY
|
No adequate and well-controlled studies in pregnant women. Embryocidal in rats and in rabbits when given 9000 times the maximum daily ophthalmic dose
|
